Glutaminase 2 (liver, mitochondrial) mRNA (GLS2 mRNA)

Glutaminase 2 (GLS2) mRNA encodes a mitochondrial enzyme that catalyzes the hydrolysis of L-glutamine to L-glutamate and ammonia, a process central to hepatic nitrogen metabolism and the urea cycle (UniProt P50136). Beyond its metabolic role, GLS2 is a key mediator of the p53-dependent antioxidant response, facilitating the production of alpha-ketoglutarate and glutathione to combat reactive oxygen species (PubMed: 20385769). In various malignancies, such as hepatocellular carcinoma and breast cancer, GLS2 expression is frequently dysregulated, contributing to metabolic reprogramming and providing a survival advantage to tumor cells under oxidative stress (PubMed: 24658273). Targeting GLS2 mRNA using RNA interference (siRNA) or antisense oligonucleotides (ASOs) represents a therapeutic strategy to disrupt these metabolic dependencies and sensitize cancer cells to apoptosis (PubMed: 30217989). While experimental models have shown that silencing GLS2 mRNA can effectively inhibit tumor growth, clinical development must address potential safety concerns related to systemic ammonia levels and liver function.

Other names

LGA mRNAGlutaminase liver isoform mRNAGLS2 transcriptL-glutamine amidohydrolase 2 mRNA

RNA interference-mediated degradation of mRNA or antisense-mediated translational inhibition to prevent the synthesis of the GLS2 enzyme.